SITAGLIPTIN PHOSPHATE (sitagliptin phosphate) by Teva is 12. First approved in 2025.
Drug data last refreshed 19h ago
12.1 Mechanism of Action ZITUVIMET XR ZITUVIMET XR tablets combine two antihyperglycemic agents: sitagliptin and metformin extended-release. Sitagliptin Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of…
Worked on SITAGLIPTIN PHOSPHATE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)